SARS-CoV-2 vaccination in IBD: more pros than cons

Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amico, Ferdinando, Rabaud, Christian, Peyrin-Biroulet, Laurent, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816748/
https://www.ncbi.nlm.nih.gov/pubmed/33473178
http://dx.doi.org/10.1038/s41575-021-00420-w
Descripción
Sumario:Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed using the experience from other vaccines or immune-mediated inflammatory disorders.

Ejemplares similares